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The forms of somatomedin present in the adult human brain have been characterized in this study. Two 
peptides were purified by acidification, size exclusion chromatography, affinity chromatography, FPLC and 
HPLC. Structural analysis identified these peptides as the variant form of IGF-1 with a truncated N-termi- 
nal region earlier isolated from human fetal brain and IGF-2. The presence of the truncated IGF-1 variant 
and IGF-2 in the human CNS suggests their role as neuropeptides. 
Somatomedin Insulin-like growth factor 1 Insulin-like growth factor 2 
Central nervous system Neuropeptide 
Amino acid sequence 
1. INTRODUCTION 
The somatomedins or insulin-like growth factors 
are a family of growth-promoting peptide hor- 
mones. Insulin-like growth factors 1 (IGF-1) and 2 
(IGF-2) were first purified and characterized from 
adult human plasma [2,3]. The primary structures 
of the prohormone forms of IGF-1 and IGF-2 have 
been deduced from their cDNA sequences [4-71. 
Variant forms of both IGF-1 [8] and IGF-2 [9,10] 
have also been identified. Whilst the 
somatomedins have been proposed to act as neural 
growth and maintenance hormones [ 111, they have 
yet to be characterized within the mature central 
nervous system. Although only immunoreactive 
IGF-2 has been detected in adult human brain ex- 
tracts and in cerebrospinal fluid [12,13], receptors 
for both IGF-1 and IGF-2 are found throughout 
the adult human brain [ 14,151. The variant form of 
IGF- 1 with a truncated N-terminal region has been 
isolated and characterized from human fetal brain 
[8]. It was unclear however, whether this variant 
IGF-1 was a specific fetal form or continued to be 
expressed in the nervous system throughout life. 
Therefore we have isolated somatomedins from 
the adult human brain and report here the 
characterization of both IGF-2 and a truncated 
IGF-1 variant identical to that found in the fetus. 
2. MATERIALS AND METHODS 
This study was conducted with ethical commit- 
tee permission. 
2.1. Purification 
Two whole brains without sign of neuro- 
pathology were removed within 9 h post mortem 
and stored frozen, the tissue was cut into small sec- 
tions and homogenized in 5 vols of 50 mM Tris- 
HCl, pH 7.7, containing 0.2 mM PMSF (phenyl- 
methylsulphonyl fluoride) and 0.1 pM pepstatin. 
The homogenate was centrifuged at 50000 x g for 
15 min. Cytosol protein was precipitated by lower- 
ing the pH to 5.5 with 1 M acetic acid, centrifuga- 
tion at 16000 x g for 30 min, further acidification 
with acetic acid to 0.1 M, incubation overnight at 
4°C and centrifugation at 16000 x g for 30 min. 
The supernatant was concentrated 3 times by 
rotary evaporation, dialyzed for 20 h with 3 
changes of 10 vols of 0.1 M acetic acid with a Spec- 
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trapor 6 dialysis membrane (Spectrum Medical In- 
dustries, USA), further concentrated by rotary 
evaporation and then chromatographed on a 
column (3 x 150 cm) of Sephadex G-50 (Phar- 
macia, Sweden) equilibrated with 0.1 M acetic acid 
at a flow rate of 24 ml/h. Active fractions were 
pooled, concentrated, dialyzed overnight against 
5 vols of 50 mM Tris-HCl, pH 7.7, and applied to 
a column (6 x 20 mm) of Sepharose 4B (Phar- 
macia, Sweden)-coupled amniotic fluid somato- 
medin carrier protein equilibrated in 50 mM Tris- 
HCl at pH 7.7. The column was washed with 3 ml 
of 50 mM Tris-HCI, pH 7.7, and 3 ml HzO. 
Activity was eluted with 6 ml of 1 M acetic acid. 
Active fractions were pooled, concentrated and ap- 
plied to an FPLC system using an HR 5/5 column 
of Mono S (Pharmacia, Sweden) equilibrated in 
10 mM ammonium acetate, pH 6.5, and 10% ace- 
tonitrile. Elution was performed at a flow rate of 
1.0 ml/min with a linear gradient of ammonium 
acetate at pH 6.5 in 10% acetonitrile. Each peak of 
activity eluted from the FPLC column was then 
lyophilized, resuspended in 30% acetic acid and 
applied to an Ultropac TSK ODS 120T column 
(4.6 x 200 mm, particle size 5 /cm) (LKB, Bromma, 
Sweden). The column was eluted with a linear gra- 
dient of acetonitrile in 0.1%. trifluoroacetic acid at 
a flow rate of 1.0 ml/min. 
2.2. Amino acid composition analysis 
Approx. 7 pmol of the native peptides were 
hydrolyzed for 24 h at 110°C with 6 M HCl/O.SOla 
phenol in evacuated tubes. Liberated amino acids 
were converted to phenylthiocarbamyl derivatives 
by coupling with phenylisothiocyanate, and the 
derivatives were identified by reverse-phase HPLC 
(Waters) on a Cis column (Spherisorb S3 ODS 2: 
3 Frn; Phase Separations, Queensferry, Wales), us- 
ing an acetonitrile gradient in a sodium phosphate 
buffer as described [16]. 
2.3. Amino acid sequence analysis 
Approx. 35 pmol of native peptide I and 
100 pmol of native peptide II were degraded in an 
Applied Biosystems 470A gas-phase sequencer. 
2.4. Fetal brain radioreceptor assay (RRA-IGF-1) 
This assay was performed as described [17]. 
Human fetal brain plasma membrane was used as 
matrix. Purified IGF-1 was iodinated by the lac- 
toperoxidase method and used as ligand. Values 
were expressed in relation to a human reference 
serum standard given an arbitrary value of 
1 U/ml. The potency of crossreaction in this assay 
is variant IGF-1, IGF-1, IGF-2 (5 : 1: 0.5) [8]. 
3. RESULTS AND DISCUSSION 
Two forms of somatomedin were purified from 
the adult human brain according to the scheme 
given in table 1. The somatomedin activity was 
monitored by fetal brain RRA-IGF- 1 [ 17 1. Cytosol 
was prepared from brain tissue, acidified and then 
Table 1 
Purification of fetal brain RRA-IGF-1 from adult human brain 
Purification step Specific activity Purification Recovery 
(U/mgl (%I 
Cytosol 0.013 1.0 100 
Acid precipitation 0.012 0.9 68 
G-50 A-pool 0.040 3.1 27 
B-pool 0.090 6.9 11 
B-pool 
Affinity chromatography a 
FPLC Mono S a 
HPLC Ultropac I 30000 
II 2900 
a 10 
a 9 
2307700 4 
223 100 4 
a Protein content not determined 
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chromatographed on a Sephadex G-SO column 
equilibrated in 0.1 M acetic acid. Fetal brain RRA- 
IGF-1 activity eluted as two peaks at positions cor- 
responding to apparent molecular masses of ap- 
prox. 12 and 4 kDa, respectively. The low- 
molecular-mass active fraction was concentrated, 
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M NH,Ac A,,, I II U/ml 
8, 
% CH,CN A2,5 
50 
LO 
30 
20 
IO 
0 
6, 
008 
006 
OOL 
002 
ooc 
-5 
-4 
-3 
-2 
-1 
-n 
I , 
0 10 20 30 
Time (mini 
eza fetal braln RRA-IGF-I 
I U/ml 
% CH,CN A,,< II U/ml 
1'0 i0 30 LO 50 
Ttme Imm) 
Fig. 1. Final steps in the purification of variant IGF-1 
and IGF-2 from adult human brain. (A) FPLC 
separation of the fetal brain RRA-IGF-1 active material. 
(B) Reverse-phase HPLC purification of peaks I (BI) 
and II (Bz) eluted from the FPLC column. Fetal brain 
RRA-IGF-1 activity is shown by the hatched area. 
dialyzed against 50 mM Tris-HCl, pH 7.7, and 
then further purified by means of affinity 
chromatography on a column of Sepharose- 
coupled somatomedin carrier protein [ 181. The ac- 
tivity was eluted from the affinity column with 
1 M acetic acid. The eluate was concentrated and 
applied to a cation exchange FPLC column 
equilibrated in 10 mM ammonium acetate, pH 6.5, 
containing 10% acetonitrile. The elution was per- 
formed with a linear gradient of lo-300 mM am- 
monium acetate, pH 6.5, in 10% acetonitrile. 
Fig.lA shows the elution profile obtained. Fetal 
brain RRA-IGF-1 activity eluted as two peaks, 
denoted I and II, at 180 and 300 mM ammonium 
acetate, respectively. Peak I contained 75% and 
peak II 25% of the total activity eluted from the 
column. After lyophilization, final purification of 
peaks I and II was obtained by reverse-phase 
HPLC (fig.lB). Both elution patterns show a 
single peak of fetal brain RRA-IGF-1 activity at 
approx. 37% acetonitrile, with peak I eluting 
slightly before peak II. In this assay, the specific 
activities of peaks I and II were approx. 30000 and 
2900 U/mg protein, respectively. The protein con- 
Table 2 
Total compositions of peptides I and II as obtained from 
analysis of acid hydrolysates, compared to the known 
compositions of IGF-1 and IGF-2 isolated from human 
adult plasma [2,3] 
Residue Peptide I Peptide II IGF-1 IGF-2 
Asx 5.0 4.6 5 3 
Glx 5.6 5.2 6 7 
Ser 4.8 7.3 5 7 
Gly 6.2 4.9 7 5 
Thr 2.5 3.9 3 4 
Ala 4.7 4.6 6 5 
His 0.0 0.1 0 0 
Pro 3.7 3.1 5 3 
Arg 4.2 8.2 6 8 
Tyr 1.8 1.8 3 3 
Val 3.4 4.0 3 4 
Met 0.5 0.0 1 0 
Cys n.d. n.d. 6 6 
Ile 1.2 0.9 1 1 
Leu 4.5 4.7 6 6 
Phe 3.0 2.8 4 4 
Lys 2.4 1.5 3 1 
n.d., not determined 
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tent was determined by amino acid analysis after Analysis by gas-phase sequencer degradations 
acid hydrolysis. The amino acid compositions of revealed peptide I to have a truncated N-terminal 
peptides I and II isolated from brain as well as region as compared to IGF-1 ffig.2A). The N- 
those of IGF-1 and IGF-2 isolated from human terminal threonine of peptide I aligned with posi- 
adult plasma [2,3] are given in table 2. These tion 4 of IGF-1. With this alignment, identical 
results show that peptides I and II have amino acid amino acid residues were observed, so that posi- 
compositions similar to IGF-1 and IGF-2, tions l- 19 in peptide I were identical with posi- 
respectively. tions 4-22 of IGF-1. This amino acid sequence is 
A 
B Domain 
Peptide I TL- GAEL 
l-19 
hIGF-1 GPETLCGAEL 
1-22 
VDALQFV-GDRG 
VDALQFVCGDRG 
El 
8 Domain 
Peptide 11 AYRPSETL -GGELVDTLQFV-GD--FYFS-PA 
1-32 
hIGF-2 AYRPSETLCGGELVDTLQFVCGDRGFYFSRFA 
1-32 
C Domain 
Peptide II -RV-RR-R 
33-N 
hIGF-2 SRVSRRSR 
33-40 
Fig.2. Analyzed regions of the amino acid sequence of peptide I as compared to the amino acid sequence of IGF-1 (A) 
[2] as well as peptide II compared to the amino acid sequence of IGF-2 (B) 131. 
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identical to that of the IGF-1 variant recently iden- 
tified in human fetal brain [8]. Variant IGF-1 most 
likely arises from posttranslational modification of 
pro-IGF-1 since Thr4 does not correspond to a 
known intron/exon hinge region [4] and there is no 
evidence for a second IGF-1 gene. Gas-phase se- 
quencer degradations of peptide II showed the 
amino acid sequence of this peptide to be identical 
to the corresponding sequence of IGF-2 (fig.2B). It 
was possible to identify Ser-29, Ala-32, Val-35 and 
Arg-38 which demonstrated that brain IGF-2 was 
not the variant form reported by Jansen et al. [9]. 
Similarly, the appearance of Val-35, Arg-37 and 
Arg-38 excluded the possibility that brain IGF-2 
was the variant form reported by Zumstein et al. 
[lo]. Thus, IGF-2 in the human brain appears 
identical to the 7.5 kDa IGF-2 in serum [3]. 
With this report, variant IGF-1 as well as IGF-2 
have now been identified in the fetal and adult 
brain of man. The truncated variant IGF-1 has so 
far only been isolated from the central nervous 
system suggesting the possibility of specific pro- 
cessing within this tissue. In preliminary studies, 
variant IGF-1 crossreacts weakly with some IGF-1 
antibodies, possibly accounting for the lack of 
IGF-1 immunoreactivity reported earlier in brain 
extracts [12]. The presence of variant IGF-1 ex- 
plains the finding of type I receptors in brain tissue 
[14,15]. These IGF-1 receptors are widely 
distributed throughout the adult human brain [ 141. 
The identification of variant IGF-1 together with 
IGF-2 as neuropeptides throughout life will 
stimulate studies to further elucidate their role in 
the central nervous system and their involvement 
in clinical disorders such as Down’s syndrome 
[l&19]. 
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